Register for our free email digests:
Are you sure you'd like to remove this alert? You will no longer receive email updates about this topic.
Latest From John Davis
Pharma company executives have limited experience with value-based contracts, but those that have experience are happy with them, says a new PwC report.
Capital Cell's effort might be the beginning of a viable alternative to VC funding for budding biotech companies.
A monthly-updated listing of recommendations from the European Medicines Agency's Committee for Medicinal Products for Human Use on the authorization of new medicines in the European Union, and updates on EU marketing authorization changes recommended by the CHMP.
Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.
Janssen-Cilag/MorphoSys's potential first-in-class psoriasis therapy has received a positive approval recommendation from Europe's top scientific advisory panel, and could become a blockbuster product despite the cluttered and changeable state of the dermatology sector.
The painful cuts in the workforce and HQ relocation planned by the new executive team at Alexion may be necessary for the long-term health of the company.